Table of Contents Author Guidelines Submit a Manuscript
Journal of Oncology
Volume 2013, Article ID 854121, 9 pages
Review Article

Predictive Factors of Response in HER2-Positive Breast Cancer Treated by Neoadjuvant Therapy

1Medical Oncology, Centre Georges François Leclerc, 21000 Dijon, France
2Medical Oncology, Centre Jean Perrin, 63000 Clermont-Ferrand, France
3Oncology Department, CHU Treichville, BP V3 Abidjan, Cote D'Ivoire

Received 24 December 2012; Revised 22 March 2013; Accepted 6 April 2013

Academic Editor: Gunter Von Minckwitz

Copyright © 2013 S. Guiu et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Since 2005, major progresses have been made in the neoadjuvant treatment of HER2-positive breast cancer. Trastuzumab introduction associated with chemotherapy has been the first major step leading to the improvement of the complete pathological response rate and, like in the adjuvant studies, better survivals. Dual HER2 blockade has been the next step and trastuzumab is associated now with other anti-HER2 therapies like lapatinib or pertuzumab, the latter being much more easy to use in combination with chemotherapy. Additional knowledge is necessary to better define within the HER2 tumor subgroup which patients could benefit more from targeted therapies. Different biomarkers have been studied to predict the response after anti-HER2 neoadjuvant therapies but until now none has been validated.